Center and Individual Willingness to Consider Heart and Lung Offers From Donors With Hepatitis C.

Autor: Ruck JM; Division of Thoracic Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland., Bowring MG; Division of Thoracic Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland., Zeiser LB; Division of Transplant Surgery, Department of Surgery, New York University Grossman School of Medicine and Langone Health, New York, New York., Durand CM; Division of Infectious Disease, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland., Massie AB; Division of Transplant Surgery, Department of Surgery, New York University Grossman School of Medicine and Langone Health, New York, New York; Division of Epidemiology, Department of Population Health, New York University Grossman School of Medicine and Langone Health, New York, New York., Segev DL; Division of Transplant Surgery, Department of Surgery, New York University Grossman School of Medicine and Langone Health, New York, New York; Division of Epidemiology, Department of Population Health, New York University Grossman School of Medicine and Langone Health, New York, New York; Scientific Registry of Transplant Recipients, Minneapolis, Minnesota., Kilic A; Division of Cardiac Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland., King EA; Division of Transplant Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland., Bush EL; Division of Thoracic Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: errol.bush@jhu.edu.
Jazyk: angličtina
Zdroj: The Journal of surgical research [J Surg Res] 2024 Oct; Vol. 302, pp. 175-185. Date of Electronic Publication: 2024 Aug 03.
DOI: 10.1016/j.jss.2024.07.043
Abstrakt: Introduction: Transplants with hearts and lungs from donors with hepatitis C virus (HCV D+) have been proven safe and effective since development of direct-acting antivirals, yet the presence of HCV + persists as a reason to decline organs.
Methods: We identified adult candidates listed January 1, 2015-March 8, 2023 for heart or lung transplant using the Scientific Registry of Transplant Recipients. We identified individual-level and center-level characteristics associated with listing to consider HCV D+ offers using multilevel logistic regression in a multivariable framework.
Results: Over the study period, the annual percentage of candidates willing to consider HCV D+ offers increased for both heart (9.5%-74.3%) and lung (7.8%-59.5%), as did the percentage of centers listing candidates for HCV D+ heart (52.9%-91.1%) and lung (32.8%-82.8%) offers. Candidates at centers with more experience with HCV D+ transplants were more likely to consider HCV D+ organ offers. After adjustment, listing center explained 70% and 78% of the residual variance in willingness to consider HCV D+ hearts and lungs, respectively.
Conclusions: Although listing for consideration of HCV D+ offers has increased, it varies by transplant center. Center-level barriers to consideration of HCV D+ organs reduce recipients' transplant access.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: